Published in J Natl Cancer Inst on December 19, 2001
The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol (2004) 5.09
Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data. J Natl Cancer Inst (2010) 3.24
Access to information sources and treatment considerations among men with local stage prostate cancer. Urology (2009) 2.15
Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer. J Gen Intern Med (2004) 1.97
Comorbidities, treatment and ensuing survival in men with prostate cancer. J Gen Intern Med (2011) 1.69
Survival after radical prostatectomy and radiotherapy for prostate cancer: a population-based study. Can Urol Assoc J (2009) 1.51
Racial Differences in the Surgical Care of Medicare Beneficiaries With Localized Prostate Cancer. JAMA Oncol (2016) 1.49
Quality of life among elderly men treated for prostate cancer with either radical prostatectomy or external beam radiation therapy. J Cancer Res Clin Oncol (2009) 1.48
Factors associated with initial treatment and survival for clinically localized prostate cancer: results from the CDC-NPCR Patterns of Care Study (PoC1). BMC Cancer (2010) 1.41
Impact of ethnicity on primary treatment choice and mortality in men with prostate cancer: data from CaPSURE. J Clin Oncol (2010) 1.26
Prostate cancer in elderly men. Rev Urol (2008) 1.19
Race, healthcare access and physician trust among prostate cancer patients. Cancer Causes Control (2009) 1.12
ProsCan for Couples: randomised controlled trial of a couples-based sexuality intervention for men with localised prostate cancer who receive radical prostatectomy. BMC Cancer (2008) 1.07
Evaluating prostate cancer mortality and competing risks of death in patients with localized prostate cancer using a comprehensive nomogram. Prostate Cancer Prostatic Dis (2012) 1.06
Supportive care needs of men living with prostate cancer in England: a survey. Br J Cancer (2008) 1.04
Trends in non-metastatic prostate cancer management in the Northern and Yorkshire region of England, 2000-2006. Br J Cancer (2009) 1.01
Factors influencing patients' acceptance and adherence to active surveillance. J Natl Cancer Inst Monogr (2012) 1.00
Patient perspective on watchful waiting/active surveillance for localized prostate cancer. J Am Board Fam Med (2012) 0.98
Radiotherapy and risks of tumor regrowth or inducing second cancer. Cancer Nanotechnol (2011) 0.97
Racial variation in the quality of surgical care for prostate cancer. J Urol (2012) 0.93
Racial variation in the pattern and quality of care for prostate cancer in the USA: mind the gap. BJU Int (2010) 0.92
What Is a "Good" Treatment Decision? Decisional Control, Knowledge, Treatment Decision Making, and Quality of Life in Men with Clinically Localized Prostate Cancer. Med Decis Making (2016) 0.88
Current Challenges in Prostate Cancer Management and the Rationale behind Targeted Focal Therapy. Adv Urol (2012) 0.87
Nadir prostate-specific antigen (PSA) level and time to PSA nadir following primary androgen deprivation therapy as independent prognostic factors in a Japanese large-scale prospective cohort study (J-CaP). J Cancer Res Clin Oncol (2014) 0.85
Severity of cardiovascular disease and health-related quality of life in men with prostate cancer: a longitudinal analysis from CaPSURE. Qual Life Res (2008) 0.83
Functional and anatomical differences between continent and incontinent men post radical prostatectomy on urodynamics and 3T MRI: a pilot study. Neurourol Urodyn (2014) 0.82
'It's not like you just had a heart attack': decision-making about active surveillance by men with localized prostate cancer. Psychooncology (2013) 0.81
Follow-up care experiences and perceived quality of care among long-term survivors of breast, prostate, colorectal, and gynecologic cancers. J Oncol Pract (2014) 0.79
The role of targeted focal therapy in the management of low-risk prostate cancer: update on current challenges. Prostate Cancer (2012) 0.79
Dynamic MRI evaluation of urethral hypermobility post-radical prostatectomy. Neurourol Urodyn (2013) 0.78
The influence of cardiovascular morbidity on the prognosis in prostate cancer. Experience from a 12-year nationwide Danish population-based cohort study. BMC Cancer (2011) 0.78
Young age under 60 years is not a contraindication to treatment with definitive dose escalated radiotherapy for prostate cancer. Radiother Oncol (2011) 0.77
The impact of increasing dose on overall survival in prostate cancer. Radiat Oncol (2015) 0.77
Controversies on individualized prostate cancer care: gaps in current practice. Ther Adv Urol (2013) 0.76
Comorbidities and Concomitant Medication Use in Men with Prostate Cancer or High Levels of PSA Compared to Matched Controls: A GPRD Analysis. J Cancer Epidemiol (2012) 0.76
The oncological outcome and validation of Japan Cancer of the Prostate Risk Assessment score among men treated with primary androgen-deprivation therapy. J Cancer Res Clin Oncol (2014) 0.75
Cavernous nerve stimulation and interposition grafting: a critical assessment and future perspectives. Rev Urol (2005) 0.75
Treatment patterns for older veterans with localized prostate cancer. Cancer Epidemiol (2015) 0.75
Emotional Distress Increases the Likelihood of Undergoing Surgery among Men with Localized Prostate Cancer. J Urol (2016) 0.75
Locoregional prostate cancer treatment pattern variation in independent cancer centers: policy effect, patient preference, or physician incentive? Health Serv Insights (2015) 0.75
Validation of a self-administered diet history questionnaire using multiple diet records. J Clin Epidemiol (1990) 8.70
Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA (2000) 6.37
Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer (2002) 5.83
A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team. JAMA (1993) 5.48
Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst (2000) 4.89
Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst (1997) 4.09
Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. JAMA (2000) 4.08
The role of increasing detection in the rising incidence of prostate cancer. JAMA (1995) 3.79
Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst (1998) 3.66
Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res (2000) 3.65
Concordance for Hodgkin's disease in identical twins suggesting genetic susceptibility to the young-adult form of the disease. N Engl J Med (1995) 3.31
The meaning and structure of species as applied to mycobacteria. Tubercle (1974) 3.22
An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res (1998) 3.22
Give us this day our daily germs. Immunol Today (1998) 3.19
Symptom assessment in schizophrenic prodromal states. Psychiatr Q (1999) 3.09
Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst (2001) 3.00
Mycobacteria as a possible cause of inflammatory bowel disease. Lancet (1978) 2.94
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer (1992) 2.91
Estimating treatment benefits for the elderly: the effect of competing risks. Ann Intern Med (1996) 2.90
I-A restricted activation by T cell lines of anti-tuberculosis activity in murine macrophages. Clin Exp Immunol (1985) 2.73
Estimating the risk of breast cancer in relation to the interval since last term pregnancy. Epidemiology (1997) 2.72
Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med (2000) 2.65
A co-operative numerical analysis of rapidly growing mycobacteria. J Gen Microbiol (1972) 2.63
Prostate cancer practice patterns and quality of life: the Prostate Cancer Outcomes Study. J Natl Cancer Inst (1999) 2.59
An outbreak of Escherichia coli O157:H7 infection from unpasteurized commercial apple juice. Ann Intern Med (1999) 2.56
Determining cause of death in prostate cancer: are death certificates valid? J Natl Cancer Inst (2001) 2.46
Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev (1998) 2.43
How environmental mycobacteria may predetermine the protective efficacy of BCG. Tubercle (1981) 2.34
A new syndrome of refractory sideroblastic anemia with vacuolization of marrow precursors and exocrine pancreatic dysfunction. J Pediatr (1979) 2.32
Characteristics of women with and without breast augmentation. JAMA (1997) 2.26
Protection of cattle from bovine tuberculosis by vaccination with BCG by the respiratory or subcutaneous route, but not by vaccination with killed Mycobacterium vaccae. Res Vet Sci (1995) 2.25
Nutrient intake and risk of subtypes of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev (2001) 2.13
Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36. Am J Hum Genet (1999) 2.12
Fruit and vegetable intakes and prostate cancer risk. J Natl Cancer Inst (2000) 2.07
A preliminary report on some studies of environmental mycobacteria. Ann Soc Belg Med Trop (1973) 2.06
Cellular immune response to common mycobacterial antigens in subjects seropositive for Trypanosoma cruzi. Lancet (1994) 2.06
Multiple skin testing in leprosy. J Hyg (Lond) (1975) 2.04
The production and preliminary investigation of Burulin, a new skin test reagent for Mycobacterium ulcerans infection. J Hyg (Lond) (1975) 2.02
Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer. Cancer Causes Control (2000) 2.00
Quality of life in survivors of colorectal carcinoma. Cancer (2000) 1.99
Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. J Urol (1997) 1.98
An evaluation of a food frequency questionnaire for assessing dietary intake of specific carotenoids and vitamin E among low-income black women. Am J Epidemiol (1991) 1.92
Embryonic-fetal erythroid characteristics of a human leukemic cell line. Proc Natl Acad Sci U S A (1980) 1.90
Role of members of the Wnt gene family in human hematopoiesis. Blood (1998) 1.86
Health outcomes after external-beam radiation therapy for clinically localized prostate cancer: results from the Prostate Cancer Outcomes Study. J Clin Oncol (2001) 1.86
Preliminary taxonomic studies on the leprosy bacillus. Br J Exp Pathol (1975) 1.83
Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Cancer (2000) 1.83
Perinatal factors and risk of breast cancer. Epidemiology (1996) 1.82
Outbreak of injection abscesses due to Mycobacterium abscessus. Arch Dermatol (1969) 1.80
Erythroid colony formation by polycythemia vera bone marrow in vitro. Dependence on erythropoietin. J Clin Invest (1977) 1.79
Breast cancer risk and "delayed" primary Epstein-Barr virus infection. Cancer Epidemiol Biomarkers Prev (2001) 1.79
Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion. Exp Hematol (2001) 1.79
Excessive zinc ingestion. A reversible cause of sideroblastic anemia and bone marrow depression. JAMA (1990) 1.78
Differences between black and white women with breast cancer in time from symptom recognition to medical consultation. Black/White Cancer Survival Study Group. J Natl Cancer Inst (1992) 1.77
BCG vaccination and cancer. Tubercle (1990) 1.76
An immunodiffusion analysis of strains of Mycobacterium ulcerans isolated in Australia, Malaya, Mexico, Uganda and Zaire. J Med Microbiol (1973) 1.76
Body size and breast cancer risk among women under age 45 years. Am J Epidemiol (1996) 1.75
Human CD34(+) stem cells express the hiwi gene, a human homologue of the Drosophila gene piwi. Blood (2001) 1.74
Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology (1998) 1.73
The treatment of lead poisoning from gunshot wounds with succimer (DMSA) J Toxicol Clin Toxicol (1994) 1.72
Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology (1999) 1.71
Mycobacterium chelonei in abscesses after injection of diphtheria-pertussis-tetanus-polio vaccine. Am Rev Respir Dis (1973) 1.70
Linkage analysis of 49 high-risk families does not support a common familial prostate cancer-susceptibility gene at 1q24-25. Am J Hum Genet (1997) 1.68
Evidence for a tumor suppressor gene distal to BRCA1 in prostate cancer. J Urol (1996) 1.66
A co-operative numerical analysis of nonscoto- and nonphotochromogenic slowly growing mycobacteria. J Gen Microbiol (1974) 1.64
Synergistic interaction between complement receptor type 2 and membrane IgM on B lymphocytes. J Immunol (1988) 1.62
Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study. Br J Cancer (2011) 1.62
Dietary relationships with early onset (under age 45) breast cancer in a case-control study in the United States: influence of chemotherapy treatment. Cancer Causes Control (1997) 1.59
Fibrin glue for partial nephrectomy. Urology (1991) 1.59
Genetics of prostate cancer: too many loci, too few genes. Am J Hum Genet (2000) 1.58
Attachment of mycobacteria to fibronectin-coated surfaces. J Gen Microbiol (1988) 1.56
Predicting extracapsular extension of prostate cancer in men treated with radical prostatectomy: results from the population based prostate cancer outcomes study. J Urol (1999) 1.56